🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Antidiabetic background therapy

Found 27 matching trials

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

PHASE3

Primary Objective: * To demonstrate the superiority of Soliqua 100/33 vers...

Status

Terminated

Location

Investigational Site Number 8400072

Start Date

2018-02-20

Trial ID

NCT03434119

Treatments Being Tested

Insulin glargine/Lixisenatide Insulin glargine (HOE901)Background therapy

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

PHASE3

Primary Objective: To demonstrate the superiority of sotagliflozin 400 mil...

Status

Completed

Location

Investigational Site Number 8406028

Start Date

2017-09-15

Trial ID

NCT03285594

Treatments Being Tested

Sotagliflozin Insulin glargine (HOE901)Placebo Oral Antidiabetes Drugs (OADs)

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo

PHASE3

Primary Objective: To demonstrate the non-inferiority of the MyStar DoseCo...

Status

Completed

Location

Investigational Site Number 276002

Start Date

2015-12

Trial ID

NCT02585674

Treatments Being Tested

Insulin glargine (U300)MyStar DoseCoach

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

PHASE4

The study was designed to investigate the optimal management of hyperglycem...

Status

Completed

Location

Diabetes and Endocrine Associates La Mesa Location

Start Date

2014-05-23

Trial ID

NCT02060383

Treatments Being Tested

Pasireotide s.c.Sitagliptin Liraglutide Insulin Pasireotide LAR Metformin

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

PHASE3

Primary Objective: To demonstrate the superiority of the insulin glargine/...

Status

Completed

Location

Investigational Site Number 8400064

Start Date

2016-07-06

Trial ID

NCT02787551

Treatments Being Tested

Insulin glargine/lixisenatide fixed ratio combination liraglutide exenatide exenatide extended-release albiglutide dulaglutide Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

PHASE4

Primary Objective: To assess the mean change in HbA1c (glycated haemoglobi...

Status

Completed

Location

Multiple Locations

Start Date

2016-11-30

Trial ID

NCT02954692

Treatments Being Tested

INSULIN GLARGINE (U300)metformin sulfonylurea meglitinides thiazolidinediones alpha-glucosidase inhibitors GLP1 Receptor Agonist Dipeptidyl peptidase-IV (DPP-IV) inhibitors Sodium-glucose transport-2 (SGLT-2) inhibitors

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

PHASE3

Primary objective: \- To evaluate the effect of lixisenatide versus placeb...

Status

Completed

Location

Investigational Site Number 840010

Start Date

2013-06

Trial ID

NCT01798706

Treatments Being Tested

Lixisenatide (AVE0010)Placebo Antidiabetic background therapy

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

PHASE3

This study will evaluate the efficacy and safety of ertugliflozin (MK-8835/...

Status

Completed

Location

Multiple Locations

Start Date

2013-12-02

Trial ID

NCT01986855

Treatments Being Tested

Ertugliflozin 5 mg Placebo 5 mg Ertugliflozin 10 mg Placebo 10 mg

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)

PHASE4

Diabetes is an independent risk factor for ischemic heart disease (CAD) and...

Status

Completed

Location

Universital Hospital Mater Domini

Start Date

2016-04

Trial ID

NCT04183868

Treatments Being Tested

Empagliflozin 10 MG Glimepiride 2 mg

To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin

N/A

To compare the risk of acute pancreatitis in patients with Type 2 diabetes ...

Status

Completed

Location

Boehringer Ingelheim International GmbH

Start Date

2021-12-20

Trial ID

NCT05162014

Treatments Being Tested

empagliflozin Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents

Previous Next